6.7.5. metastatic crpc. remainder section focuses management men proven mcrpc conventional imaging. 6.7.5.1. conventional androgen deprivation crpc eventually men pca show evidence disease progression despite castration. two trials shown marginal survival benefit patients remaining lhrh analogues second- thirdline therapies . however, absence prospective data, modest potential benefits continuing castration outweigh minimal risk treatment. addition, subsequent treatments studied men ongoing androgen suppression, therefore, continued patients.